LEARN MORE
Not actual size.
NOW ALSO APPROVED
FOR CHRONIC MIGRAINE
THE ONLY PILL OF ITS KIND*
APPROVED TO PREVENT
MIGRAINES OF ANY FREQUENCY
*Once-daily oral CGRP blocker

WHAT IS QULIPTA® (atogepant)?

QULIPTA is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Do not take QULIPTA® (atogepant) if you have had an allergic reaction to atogepant or any ingredients in QULIPTA.

Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you:

Have kidney problems or are on dialysis

Have liver problems

Are pregnant or plan to become pregnant. It is not known if QULIPTA will harm your unborn baby

Are breastfeeding or plan to breastfeed. It is not known if QULIPTA passes into your breast milk. Talk to your healthcare provider about the
best way to feed your baby while taking QULIPTA

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines.

QULIPTA can cause serious allergic reactions, like anaphylaxis, that can happen when you take QULIPTA or days after. Stop taking QULIPTA and get emergency medical help right away if you get any of the following symptoms, which may be part of a serious allergic reaction: swelling of the face, lips, or tongue; itching; trouble breathing; hives; or rash.

The most common side effects of QULIPTA are nausea, constipation, and fatigue/sleepiness. These are not all the possible side effects of QULIPTA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

© 2023 AbbVie. All rights reserved.

US-QLP-230049 04/23

INDICATION AND IMPORTANT SAFETY INFORMATION
PLEASE CLICK HERE FOR FULL PATIENT INFORMATION